# Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)

> **NCT04592653** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Mural Oncology, Inc** · enrollment: 78 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **BIOLOGICAL:** Nemvaleukin alfa
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04592653
- **Lead sponsor:** Mural Oncology, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-30
- **Primary completion:** 2024-07
- **Final completion:** 2024-12
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2024-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04592653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04592653, "Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04592653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*